Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire

Aug.08.2022
Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire
The Philippines' proposed e-cigarette law facing opposition from health officials and advocates for public health.

On his first day in office, Philippine President Marcos vetoed the bill to establish the special ecological zone at the Bura-gan airport city, sending a message that public interest should prevail over commercial profits.


However, the proposed Nicotine and Non-Nicotine Aerosol Products Regulation Act appears to be anything but. The President allowed the act to lapse on July 25th. While the e-cigarette bill would expand its market base and bring more funding to the tobacco industry, it is seen as harmful to health because it would allow individuals as young as 18 to buy, use, and sell e-cigarettes and heated tobacco products, and would lift flavor restrictions on e-cigarette liquids.


The National Health, Food and Drug Administration, Ministry of Education, Ministry of Finance, as well as dozens of medical associations and former health ministers, are strongly lobbying against an electronic cigarette bill. They believe that this puts the country's youth at risk of harmful effects from electronic cigarettes. Former health minister Francisco Duque opposed the claim that electronic cigarettes can help people quit smoking. He said that they typically have the opposite effect as they lead people to engage in more bad habits such as drinking and illegal drug use.


The Philippines is one of the countries with the highest smoking rates among adults and youth around the world. The Global Adult Tobacco Survey in 2015 revealed that nearly 23.8% of Filipino adults used some form of tobacco, with 22.7% of the population being smokers and 18.7% of them being daily smokers.


Approximately 117,000 people die each year in the country due to tobacco-related illnesses such as lung cancer and cardiovascular disease. The cost of treating the four main diseases caused by tobacco use in the Philippines is estimated to be 46.4 billion pesos.


Child rights activists and tobacco control advocates believe that the e-cigarette bill is a "victory for tobacco capital.


The public interest law organization, ImagineLaw, has stated that allowing this bill to become law would be a "betrayal of public health" and a "regrettable development" in light of President Marcos' promise to rebuild the country better.


When the President does not take action after receiving a legislative measure for 30 days, the legislation expires. The previous Congress shelved the e-cigarette bill for five months and on June 24th forwarded a registered copy to Malacañang, just six days before then-President Rodrigo Duterte's term ended.


Health experts and tobacco control advocates are calling for the rejection of the proposed bill, as its provisions conflict with public health goals and international standards, particularly in light of the Supreme Court's ruling in late June upholding the FDA's jurisdiction over tobacco products and reaffirming the country's commitment to the World Health Organization's Framework Convention on Tobacco Control.


Marcos hails from the Ilocos region where tobacco is the main cash crop. Allowing the electronic cigarette bill to expire puts narrow interests ahead of the common good.


Some are calling for the immediate convening of the Legislative-Executive Development Advisory Council (LEDAC) by the President and have pointed out that while the veto power is within the President's rights, its frequent use may strain relations between the executive and legislative branches of government.


In the coming days when meeting with congressional leaders, it should be clear that they will prioritize legislation that serves the public interest, rather than industry profits. The public interest should never be relegated to a secondary position.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning only.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's ability, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI nicotine pouch brand Nordic Spirit has entered a long-term partnership with Manchester’s Co-op Live, becoming the venue’s Official Nicotine Pouch Partner. The 23,500-capacity venue is the UK’s largest indoor live entertainment arena. Nordic Spirit will run in-venue activations for existing adult nicotine consumers and sell products at selected arena bars. The agreement was entered into before the relevant UK sponsorship restrictions were introduced, while the government intends to implement a comprehensive ban on advertising and sponsorship of vaping and nicotine products from June 1, 2027.
Sep.07
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14